Wegovy, Ozempic or Mounjaro? Drugs could remake the weight loss industry
A report by the World Health Organization in 2022 showed that obesity has almost tripled since 1975. More than a billion people are clinically obese worldwide, including 650 million adults, 340 million adolescents and 39 million children. The prevalence of obesity is expected to increase if current trends continue, but new obesity treatments are entering the market.
Wegovy is one of many new “miracle” drugs that promise to revolutionize the weight loss industry.
Praised by celebrities and social media influencers, Wegovy has been approved for use in the US, as well as in the UK’s free healthcare system, where it will be available to patients in spring 2023.
“This drug really changes the paradigm of treating obesity. You get 15-17% weight loss with a weekly injection,” Peter Verdult, pharmaceutical analyst at Citi, told CNBC.
A report from the World Health Organization in 2022 showed that obesity has nearly tripled since 1975 and is still rising. More than one billion people are clinically obese worldwide, including 650 million adults, 340 million adolescents and 39 million children.
But the long-term consequences of these drugs remain unknown. They’re expensive, there’s fear they’ll fall into the hands of people who don’t need them – and people who want to maintain their weight may have to keep them for life.
Watch the video above to learn more.
#Wegovy #Ozempic #Mounjaro #Drugs #remake #weight #loss #industry, 1680515070